{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-066225","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2022-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.205099+00:00","generated_at":"2026-06-25T05:53:00.574632+00:00","sec_items":["1.01","1.02","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TELA Bio enters $50M credit facility with MidCap; repays $33.2M OrbiMed debt","bullets":["Borrowed $40.0M upfront from $50.0M term loan facility; unused $10M Tranche 2 conditional on reaching $65M net revenue by FY2023.","Repaid outstanding $33.2M under existing OrbiMed credit agreement.","Loan bears interest at 6.25% plus one-month Term SOFR (floor 1.0%), matures May 1, 2027.","Interest-only for 36 months, extendable to 48 months subject to covenant compliance; then amortization.","Prepayment fee 3% in year one, 2% year two, 1% year three; plus 5% exit fee on principal."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-066225","json":"https://secwatch.observer/filing/0001104659-22-066225.json","markdown":"https://secwatch.observer/filing/0001104659-22-066225.md","text":"https://secwatch.observer/filing/0001104659-22-066225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465922066225/0001104659-22-066225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465922066225/tm2217085d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T05:53:00.574632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}